In obese adults with existing heart disease but no diabetes, a weekly injection of semaglutide at 2.4 mg is associated with a lower rate of serious heart-related events such as heart attack or stroke.
Mechanism
Synthesis from 1 study
This medicine reduces food intake so much that the body starts burning fat nonstop, which creates more harmful molecules inside cells. At the same time, it doesn't get enough vitamins and proteins to clean those molecules up. This imbalance accidentally makes blood vessels less inflamed and less...
Most probable mechanism
The medicine makes the body burn more fat for energy because it reduces hunger and food intake. This forces the energy factories in cells (mitochondria) to work harder, which creates more harmful byproducts called free radicals. At the same time, the body gets fewer nutrients and vitamins needed to clean up those byproducts. This imbalance damages blood vessel walls and reduces the buildup of dangerous plaques, lowering the chance of heart attacks and strokes.
GLP-1 receptor agonists bind to receptors in the brain and gut, suppressing appetite and delaying gastric emptying, leading to chronic reduction in nutrient intake.
Reduced nutrient availability shifts metabolism toward fatty acid oxidation to sustain mitochondrial ATP production, increasing electron flux through the electron transport chain.
Increased electron transport chain activity elevates production of reactive oxygen species, overwhelming antioxidant systems due to limited precursor availability.
Reduced dietary intake limits availability of micronutrients (e.g., selenium, magnesium, B vitamins) and amino acids (e.g., cysteine), impairing function of antioxidant enzymes like glutathione peroxidase and NADPH regeneration.
Redox imbalance increases lipid peroxidation and oxidative damage in vascular endothelial cells and macrophages, reducing plaque instability and inflammatory cell recruitment.
Oxidative stress in vascular tissues suppresses pro-inflammatory signaling pathways and reduces foam cell formation, slowing atherosclerosis progression.
Less supported by current evidence, but not ruled out
The medicine reduces food intake so much that the body starts breaking down muscle for energy, which changes how the body uses fuel and may indirectly affect heart function by altering energy availability.
Chronic reduction in nutrient intake activates AMPK in skeletal muscle and liver.
AMPK activation inhibits mTOR signaling, reducing protein synthesis and promoting muscle breakdown.
Loss of lean mass alters systemic metabolic demand and substrate partitioning, potentially reducing cardiac workload and energy expenditure.
The medicine causes the body to use up a key energy molecule called NAD+ faster than it can be replaced, which weakens the cell's ability to make energy and fight damage, especially in blood vessels.
Chronic GLP-1 receptor activation sustains low-grade inflammation in adipose tissue, increasing activity of NAD+-consuming enzymes like CD38 and PARP-1.
Reduced dietary intake limits precursors for NAD+ synthesis, such as niacin and tryptophan, impairing NAD+ regeneration.
NAD+ depletion reduces mitochondrial ATP production and cytosolic NADPH availability, weakening antioxidant defenses and increasing oxidative stress in vascular tissue.
Evidence from Studies
Supporting (1)
Community contributions welcome
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.